Track Pfizer Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: 1.31 %
Low
4,425.0
High
4,608.9
1 Month returns: 0.09 %
Low
4,360.1
High
4,686.8
1 Year returns: -22.54 %
Low
4,360.1
High
5,878.6
3 Year CAGR: 5.96 %
Low
3,701.0
High
6,451.1
5 Year CAGR: -4.65 %
Low
3,408.0
High
6,451.1
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Pfizer Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Pfizer Ltd. Shareholding Pattern
Quarterly breakdown of Pfizer Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Pfizer Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Pfizer Ltd.?
The current share price of Pfizer Ltd. is ₹ 4,532.10 as of 8 Jul 2026.
What is the market capitalisation of Pfizer Ltd.?
The market capitalisation of Pfizer Ltd. stands at ₹ 20,733.50 Cr.
What is the PE ratio of Pfizer Ltd.?
The Price-to-Earnings (PE) ratio of Pfizer Ltd. is 28.70 as of the latest trailing twelve months data.
What is the ROE and ROCE of Pfizer Ltd.?
Pfizer Ltd. has a Return on Equity (ROE) of 17.16% and a Return on Capital Employed (ROCE) of 19.69% as per the latest financial reports.
What is the 52-week high and low of Pfizer Ltd.?
The 52-week high of Pfizer Ltd. is - and the 52-week low is -.
What is the dividend yield of Pfizer Ltd.?
The dividend yield of Pfizer Ltd. is 0.77% based on the current market price.
What is the FII and DII holding in Pfizer Ltd.?
Foreign Institutional Investors (FII) hold 2.81%, Domestic Institutional Investors (DII) hold 16.85% and retail/public investors hold 13.66% of Pfizer Ltd. shares.
What sector does Pfizer Ltd. belong to?
Pfizer Ltd. operates in the Healthcare sector. 80% of analysts have a Buy or Strong Buy rating on Pfizer Ltd. with a consensus target price of ₹ 5,750.00, implying 26.87% upside from current levels.
What is the beta of Pfizer Ltd.?
The beta of Pfizer Ltd. is 0.69, indicating its price volatility relative to the broader market. Over the past 1 year, Pfizer Ltd. has delivered an absolute return of -20.17%.
What is the RSI of Pfizer Ltd.?
The 14-day Relative Strength Index (RSI) of Pfizer Ltd. is 49.63, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Company Profile
Overview of Pfizer Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approve...
Fundamental analysis overview of Pfizer Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
High and improving operating margin
The company reported strong operating margin of 33.59% for 12-month ended 31 Mar 2026 and operating margin improved by 373 bps from 1 year ago
What is Operating profit margin?
Low Debt to Equity, not much change from last year
The company has low Debt to Equity of 0.02 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.01 in the last 1 year
What is Debt to Equity?
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Expensive and at same valuation levels as industry median P/E
PE TTM of 28.7 indicates that the stock is expensive on a standalone basis. Discount to industry median P/E is modest at -5.5%
What is P/E Ratio?
Median: 30.37
Value 28.7
-215.443255.34
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -2.01% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -5.88% for 12-month ended 31 Mar 2026 and the growth was 14.0 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.77%
What is Dividend yield?
Neutral
High ROE but declining trend
The company reported strong ROE of 17.16% for 12-month ended 31 Mar 2026 but ROE declined by -249 bps from 1 year ago
What is ROE (FY)?
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 10.45% for 12-month ended 31 Mar 2026 and the growth was 0.79 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 11.24
Value 10.45
-82.35114662
Company's earnings are of moderate quality
Earnings quality score of 67.3 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
67.3 / 100
No red flags found!
No significant red flags found in the stock.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Corporate Actions
History of Pfizer Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.